Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXALT: Bydureon for Alcohol Dependence
NCT03232112Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol dependence comparing Exenatide with Placebo (2 arms). Primary endpoint: Heavy drinking days. Started Aug 2017; status: completed.
02
Drugs
exenatide
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT03232112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232112.